title: Significant decrease in the prevalence of Wuchereria bancrofti infection in anopheline mosquitoes following the addition of albendazole to annual, ivermectin-based, mass treatments in Nigeria.
abstract: A prospective entomological survey was conducted in four sentinel villages in central Nigeria from 1999-2002, to assess the impact of annual, single-dose, mass drug administrations (MDA), with a combination of ivermectin and albendazole, on the transmission of Wuchereria bancrofti. As they were also endemic for human onchocerciasis, the four villages had received annual MDA based on ivermectin alone for 7 years prior to the addition of albendazole. Resting Anophelines gambiae s. l., An. funestus and Culex species were collected from 92 sequentially sampled households and dissected. Mosquitoes harbouring any larval stage of W. bancrofti were classified as 'infected', and those containing the third-stage larvae of the parasite were classified as 'infective'. Over the 41-month observation period, 4407 mosquitoes were captured and dissected, of which 64% were An. gambiae s. l., 34% An. funestus, and 1% Culex species. The baseline data, from dissections performed before the addition of albendazole to the MDA, showed high prevalences of mosquito infection (8.9%) and infectivity (2.9%), despite apparently good treatment coverages during the years of annual ivermectin monotherapy. Only the anopheline mosquitoes were found to harbour W. bancrofti larvae. After the third round of MDA with the ivermectin-albendazole combination, statistically significant decreases in the prevalences of mosquito infection (down to 0.6%) and infectivity (down to 0.4%) were observed (P<0.0001 for each). The combination of albendazole and ivermectin appears to be superior to ivermectin alone for reducing the frequency of W. bancrofti infection in mosquitoes.
authors.affiliation: The Carter Center, One Copenhill, 453 Freedom Parkway, Atlanta, GA 30307, USA. sdsulli@emory.edu
authors.forename: F O
authors.initials: FO
authors.lastname: Richards
authors.forename: D D
authors.initials: DD
authors.lastname: Pam
authors.forename: A
authors.initials: A
authors.lastname: Kal
authors.forename: G Y
authors.initials: GY
authors.lastname: Gerlong
authors.forename: J
authors.initials: J
authors.lastname: Onyeka
authors.forename: Y
authors.initials: Y
authors.lastname: Sambo
authors.forename: J
authors.initials: J
authors.lastname: Danboyi
authors.forename: B
authors.initials: B
authors.lastname: Ibrahim
authors.forename: A
authors.initials: A
authors.lastname: Terranella
authors.forename: D
authors.initials: D
authors.lastname: Kumbak
authors.forename: A
authors.initials: A
authors.lastname: Dakul
authors.forename: A
authors.initials: A
authors.lastname: Lenhart
authors.forename: L
authors.initials: L
authors.lastname: Rakers
authors.forename: J
authors.initials: J
authors.lastname: Umaru
authors.forename: S
authors.initials: S
authors.lastname: Amadiegwu
authors.forename: P C
authors.initials: PC
authors.lastname: Withers
authors.forename: H
authors.initials: H
authors.lastname: Mafuyai
authors.forename: M Y
authors.initials: MY
authors.lastname: Jinadu
authors.forename: E S
authors.initials: ES
authors.lastname: Miri
authors.forename: A
authors.initials: A
authors.lastname: Eigege
mesh_terms: D015766:Albendazole / Q000627:therapeutic use*; D000818:Animals; D000852:Anopheles / Q000469:parasitology; D000871:Anthelmintics / Q000627:therapeutic use*; D003465:Culex / Q000469:parasitology; D009033:Culicidae / Q000469:parasitology*; D004359:Drug Therapy, Combination; D004605:Elephantiasis, Filarial / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D019353:Endemic Diseases / Q000517:prevention & control; D004812:Epidemiologic Methods; D005369:Filaricides / Q000627:therapeutic use; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D009549:Nigeria / Q000453:epidemiology; D012423:Rural Health
chemical_list: D000871:Anthelmintics; D005369:Filaricides; D007559:Ivermectin; D015766:Albendazole